Anzeige
Mehr »
Login
Dienstag, 21.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News! 22 Jahre "BlueChip"-Power nun bei NurExone!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0B7QK | ISIN: GB0034330679 | Ticker-Symbol: DWV
Frankfurt
20.05.24
09:18 Uhr
0,220 Euro
-0,018
-7,56 %
Branche
Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ANGLE PLC Chart 1 Jahr
5-Tage-Chart
ANGLE PLC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2380,26020.05.

Aktuelle News zur ANGLE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAngle reports promising results from Parsortix study1
DoAngle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix113INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALSThe study investigated 123 metastatic ovarian cancer...
► Artikel lesen
03.05.Angle signs AstraZeneca deal to develop prostate cancer assay2
03.05.Angle shares up on assay development deal with AstraZenaca1
03.05.AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal1
03.05.Angle strikes supplier deal with AstraZeneca7
03.05.Angle PLC Announces New Commercial Agreement with Large Pharma196ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY),...
► Artikel lesen
24.04.SmallCap Risers and Fallers: Filtronic, Angle, Aptamer2
24.04.Angle inks deal with AstraZeneca3
24.04.Angle shares jump on supplier agreement with with AstraZeneca4
24.04.Angle agrees deal with Astrazeneca for tech to kill cancer cells4
24.04.Liquid biopsy firm Angle signs new commercial agreement with AstraZeneca4
24.04.ANGLE Reaches Deal With AstraZeneca To Advance DDR Assay For Circulating Tumor Cell Detection237LONDON (dpa-AFX) - ANGLE plc (AGL.L, ANPCY) said that it has reached an agreement with AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response...
► Artikel lesen
24.04.Angle PLC Announces New Commercial Agreement with AstraZeneca161ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE / April 24, 2024 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a...
► Artikel lesen
22.04.IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide1
22.04.Angle granted European patent for CellKeep, US patent imminent1
22.04.Angle PLC Announces US and EU Patents for Innovative CellKeep Slide130Proprietary cell recovery device and method eliminates over 70% of CTC cell loss from standard microscopy techniques increasing assay sensitivity GUILDFORD, SURREY / ACCESSWIRE / April 22, 2024 / ANGLE...
► Artikel lesen
08.04.Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024339PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug conjugates presented at internationally renowned...
► Artikel lesen
22.03.Angle PLC Announces Parsortix at European Breast Cancer Conference272PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait...
► Artikel lesen
22.01.IN BRIEF: Angle highlights supportive data for DNA analysis tool1
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1